A landmark trial involving Merck and Moderna has strengthened hopes that personalised cancer vaccines could become an important new weapon against melanoma and, eventually, a much wider range of cancers.
The companies said their customised mRNA vaccine, used alongside Merck’s immunotherapy drug Keytruda, significantly reduced the chances of melanoma returning or spreading in a large study involving more than 1,000 patients.
The participants had undergone surgery to remove their tumours but remained at high risk of the disease coming back.
The findings are being viewed as an important milestone for personalised cancer treatment because the vaccine is designed around the unique genetic mutations found in each patient’s tumour.
How Personalised Vaccines Differ From Traditional Cancer Treatment
Conventional chemotherapy works by attacking rapidly dividing cells, meaning healthy cells can also be damaged in the process.
Immunotherapy takes a different approach by stimulating the body’s immune defences so they can recognise and attack cancer.
The personalised vaccine takes that strategy a step further.
It is designed to teach the immune system to recognise mutations that are specific to an individual patient’s tumour, potentially allowing the body to identify and destroy cancer cells while leaving healthy tissue largely untouched.
The approach has generated considerable excitement among cancer specialists, who believe the technology could eventually be adapted to treat many different tumour types.
Trial Results Mark a Major Milestone
Merck and Moderna reported that their phase 3 study found a substantial reduction in the risk of melanoma returning when the personalised vaccine was combined with Keytruda.
The companies have not yet released the complete dataset, and researchers will continue monitoring participants to establish whether the treatment ultimately improves overall survival.
Earlier five-year results from a mid-stage trial had already shown that adding the personalised vaccine to Keytruda reduced the risk of melanoma recurrence by 50% and lowered the risk of the disease spreading to distant parts of the body by 59%.
The latest findings have now provided further support for taking the treatment approach into broader clinical use.
What the Treatment Actually Involves
The treatment, known as intismeran autogene, combines Keytruda with an individually tailored mRNA vaccine.
Patients can receive as many as nine doses of Keytruda, administered approximately every six weeks, alongside up to nine doses of the personalised vaccine.
Keytruda is already used following melanoma surgery to reduce the risk of recurrence and is typically administered every three to six weeks for as long as a year.
Its known side-effects can include fatigue, diarrhoea, skin rashes and inflammation affecting joints, muscles and, in some cases, healthy organs.
Importantly, Merck and Moderna said the addition of the vaccine did not produce any new safety signals in the trial.
Doctors See Potential Beyond Melanoma
Cancer specialists say the significance of the results could extend far beyond melanoma.
Dr Ryan Sullivan, director of the Centre for Melanoma at Mass General Brigham Cancer Institute, described the development as highly significant for the wider cancer field.
He said the results could encourage further investment and research into personalised vaccines for other malignancies.
Dr Julie Gralow, chief medical officer of the American Society of Clinical Oncology, similarly described the results as a major advance that helps validate mRNA technology as a potential cancer treatment.
Melanoma was considered a particularly suitable cancer for this approach because these tumours often contain a large number of mutations.
The greater number of mutations can provide the immune system with more potential targets to recognise.
Researchers believe other cancers with similarly high mutation levels could also respond to personalised vaccine strategies.
The Pipeline Is Already Expanding
Merck and Moderna are not limiting their research to melanoma.
The companies are conducting late-stage studies involving non-small cell lung cancer in patients whose tumours have been surgically removed.
They are also testing the treatment approach in mid-stage trials involving bladder and kidney cancers.
Earlier-stage research is under way in pancreatic and stomach cancers, with results from some of these studies expected over the next one or two years, according to Moderna president Stephen Hoge.
Other pharmaceutical companies are pursuing similar strategies.
Roche and BioNTech are testing an mRNA-based personalised treatment called autogene cevumeran in patients with colon and pancreatic cancers following surgery.
Results from the colon cancer study are expected in 2027, while the pancreatic cancer programme is expected to produce results later in the next decade.
Why Melanoma Was an Important Testing Ground
Doctors treating patients after successful melanoma surgery often face a difficult decision.
Keytruda can lower the chance of recurrence, but immunotherapy can also cause potentially serious side-effects.
For some patients, the estimated risk of their cancer returning may be relatively modest.
That can make the decision over whether to undergo additional treatment particularly complicated.
Dr Elizabeth Buchbinder, a melanoma specialist at Mass General Brigham Cancer Institute, said the additional protection offered by a personalised vaccine could potentially alter that risk-benefit calculation.
If the vaccine can substantially reduce recurrence without adding significant new toxicity, patients and doctors may have a stronger reason to choose preventative treatment after surgery.
Safety Findings Add to the Optimism
Safety remains one of the most important questions surrounding any new cancer therapy.
In the earlier mid-stage study, researchers did not find an increase in serious side-effects after adding the mRNA vaccine to Keytruda.
Hoge said many of the reactions observed with the vaccine resembled those commonly associated with familiar vaccinations, including flu and Covid vaccines.
The phase 3 study remains ongoing, however, meaning researchers will continue monitoring patients before drawing final conclusions about long-term survival.
The Numbers Behind the Breakthrough
The scale of the research and the early effectiveness results help explain why the findings have attracted so much attention.
- More than 1,000: The number of melanoma patients involved in the large-stage trial of the personalised vaccine combined with Keytruda.
- 50%: The reduction in the risk of melanoma recurrence observed over five years in an earlier mid-stage study.
- 59%: The reduction in the risk of the cancer spreading to distant parts of the body in that earlier study.
The results suggest that a vaccine designed around an individual tumour may provide an additional layer of protection after surgery.
A Potential Shift in Cancer Care
The promise of personalised cancer vaccines lies in their ability to make treatment increasingly specific to the biology of an individual patient’s disease.
Rather than relying on a single therapy designed for every patient with the same cancer, researchers are attempting to use genetic information from a tumour to create a treatment tailored to that particular disease.
The concept remains under investigation, but the latest melanoma results have provided some of the strongest evidence yet that personalised mRNA vaccines could have a meaningful role in cancer care.
What Comes Next?
The immediate focus will be on completing the phase 3 trial and determining whether the reduction in recurrence and metastatic disease translates into longer overall survival.
At the same time, researchers will be watching closely for results from trials involving lung, bladder, kidney, pancreatic, stomach and colon cancers.
If similar benefits emerge across several tumour types, personalised cancer vaccines could move from an experimental technology into a much broader component of post-surgery cancer treatment.
Dr Robert Vonderheide, director of Penn Medicine’s Abramson Cancer Centre and president-elect of the American Association for Cancer Research, said the results provide reason for optimism as researchers await findings from other ongoing studies.
Summary
The Merck-Moderna results represent an important development in the effort to personalise cancer treatment.
Their mRNA vaccine is designed to train the immune system to recognise mutations unique to a patient’s tumour, while Keytruda helps strengthen the body’s broader immune response.
The early evidence shows significant reductions in the risk of melanoma returning or spreading, without an apparent increase in new serious side-effects.
Researchers now want to establish whether those benefits can be reproduced in other cancers and, most importantly, whether they lead to longer survival.
For now, the technology remains under clinical investigation.
But with major trials already under way across several cancer types, personalised mRNA vaccines are rapidly becoming one of the most closely watched areas of modern oncology.
